Clinical consequences related to a defective elimination of clobazam caused by homozygous mutated CYP2C19 allele

References

• Fukasawa T, Suzuki A, Otani K. Effects of genetic polymorphism of cytochrome P450 enzymes on the pharmacokinetics of benzodiazepines. J Clin Pharm Ther. 2007;32:333–341.
   PubMed Web of Science ®Google Scholar
• Ng Y, Collins SD. Clobazam. Neurother J Am Soc Exp. 2007;4:138–144.
   PubMed Web of Science ®Google Scholar
• Iwasaki T, Nonoda Y, Ishida T, et al. Correlating blood and urinary concentrations of clobazam doses in Japanese children and adolescents with intractable epilepsy. Biomed Chromatogr. 2017;31:e3848.
   Web of Science ®Google Scholar
• Kosaki K, Tamura K, Sato R, et al. A major influence of CYP2C19 genotype on the steady-state concentration of N-desmethylclobazam. Brain Dev. 2004;26:530–534.
   PubMed Web of Science ®Google Scholar
• Bun H, Coassolo P, Gouezo F, et al. Time-dependence of clobazam and N-demethylclobazam kinetics in healthy volunteers. Int J Clin Pharmacol Ther Toxicol. 1986;24:287–293.
   PubMedGoogle Scholar
• Bentué-Ferrer D, Tribut O, Verdier MC, et al. Therapeutic drug monitoring of clobazam. Therapie. 2010;65:225–231.
   Web of Science ®Google Scholar
• de Leon J, Spina E, Diaz FJ. Clobazam therapeutic drug monitoring: a comprehensive review of the literature with proposals to improve future studies. Ther Drug Monit. 2013;35:30–47.
   PubMed Web of Science ®Google Scholar
• Giraud C, Tran A, Rey E, et al. In vitro characterization of clobazam metabolism by recombinant cytochrome P450 enzymes: importance of cyp2c19. Drug Metab Dispos. 2004;32:1279–1286.
   PubMed Web of Science ®Google Scholar
• Turcant A, Premel-Cabic A, Cailleux A, et al. Toxicological screening of drugs by microbore high-performance liquid chromatography with photodiode-array detection and ultraviolet spectral library searches. Clin Chem. 1991;37:1210–1215.
   PubMed Web of Science ®Google Scholar
• Goldstein JA, de Morais SM. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics. 1994;4:285–299.
   PubMedGoogle Scholar
• Goldstein JA, Ishizaki T, Chiba K, et al. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics. 1997;7:59–64.
   PubMedGoogle Scholar
• Wijnen P, Op Den Buijsch RAM, Drent M, et al. The prevalence and clinical relevance of cytochrome P450 polymorphisms. Aliment Pharmacol Ther. 2007;26:211–219.
   PubMed Web of Science ®Google Scholar
• De Morais SM, Wilkinson GR, Blaisdell J, et al. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem. 1994;269:15419–15422.
   PubMed Web of Science ®Google Scholar
• Desta Z, Zhao X, Shin JG, et al. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet. 2002;41:913–958.
   PubMed Web of Science ®Google Scholar
• Seo T, Nagata R, Ishitsu T, et al. Impact of CYP2C19 polymorphisms on the efficacy of clobazam therapy. Pharmacogenomics. 2008;9(5):527–537.
   PubMed Web of Science ®Google Scholar
• Contin M, Sangiorgi S, Riva R, et al. Evidence of polymorphic CYP2C19 involvement in the human metabolism of N-desmethylclobazam. Ther Drug Monit. 2002;24:737.
   PubMed Web of Science ®Google Scholar
• Proença P, Teixeira H, Pinheiro J, et al. Forensic intoxication with clobazam: HPLC/DAD/MSD analysis. Forensic Sci Int. 2004;143:205–209.
   PubMed Web of Science ®Google Scholar
• Pok PRP, Mauras M, Léger MNDS, et al. Blood concentrations of clobazam and norclobazam in a lethal case involving clobazam, meprobamate and clorazepate. Leg Med. 2010;12:300–304.
   PubMed Web of Science ®Google Scholar
• Bardy AH, Seppälä T, Salokorpi T, et al. Monitoring of concentrations of clobazam and norclobazam in serum and saliva of children with epilepsy. Brain Dev. 1991;13:174–179.
   PubMed Web of Science ®Google Scholar
• Riva R, Albani F, Contin M, et al. Pharmacokinetic interactions between antiepileptic drugs. Clinical considerations. Clin Pharmacokinet. 1996;31:470–493.
   PubMed Web of Science ®Google Scholar
• Russell GR, Phelps SJ, Shelton CM, et al. Impact of drug interactions on clobazam and N-desmethylclobazam concentrations in pediatric patients with epilepsy. Ther Drug Monit. 2018;40(4):452–462.
   PubMed Web of Science ®Google Scholar
• Hole K, Wollmann BM, Nguyen C, et al. Comparison of CYP3A4-inducing capacity of enzyme-inducing antiepileptic drugs using 4β-hydroxycholesterol as biomarker. Ther Drug Monit. 2018;40:463.
   PubMed Web of Science ®Google Scholar
• Derungs A, Donzelli M, Berger B, et al. Effects of cytochrome P450 inhibition and induction on the phenotyping metrics of the basel cocktail: a randomized crossover study. Clin Pharmacokinet. 2016;55:79–91.
   PubMed Web of Science ®Google Scholar
• King N, Tran M-H. Long-acting anticoagulant rodenticide (superwarfarin) poisoning: a review of its historical development, epidemiology, and clinical management. Transfus Med Rev. 2015;29:250–258.
   PubMed Web of Science ®Google Scholar
• HLA B∗5701 status, disease progression, and response to antiretroviral therapy. AIDS Lond Engl. 2013;27:2587–2592.
   Google Scholar
• Tamm R, Mägi R, Tremmel R, et al. Polymorphic variation in TPMT is the principal determinant of TPMT phenotype: a meta-analysis of three genome-wide association studies. Clin Pharmacol Ther. 2017;101:684–695.
   PubMed Web of Science ®Google Scholar
• Lin X, Li Z, Yan M, et al. Population pharmacokinetics of voriconazole and CYP2C19 polymorphisms for optimizing dosing regimens in renal transplant recipients. Br J Clin Pharmacol. 2018;84:1587–1597.
   PubMed Web of Science ®Google Scholar
• Amsden JR, Gubbins PO. Pharmacogenomics of triazole antifungal agents: implications for safety, tolerability and efficacy. Expert Opin Drug Metab Toxicol. 2017;13:1135–1146.
   PubMed Web of Science ®Google Scholar